Stephens Investment Management Group LLC
Position in TVTX — Travere Therapeutics, Inc.
CIK 1314440
LITTLE ROCK, AR
Position in TVTX
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$106,536,020
+$53,103,596 QoQ
Shares Held
1,875,304
+4.3% QoQ
Ownership
1.99%
of shares outstanding
% of Portfolio
1.16%
of 13F equity value
Holder Rank
#13
of 317 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 96%
None 4%
Common Shares in TVTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Stephens Investment Management Group LLC holds $614,628,718 across 6 Biotechnology names. TVTX ranks #4 (17.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
475,609 | $150,335,248 | |
| 2 | EXEL |
Exelixis, Inc.
|
2,710,011 | $147,451,698 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
1,392,819 | $109,015,943 | |
| 4 | TVTX |
Travere Therapeutics, Inc.
This page
|
1,875,304 | $106,536,020 | |
| 5 | TECH |
BIO-TECHNE Corp
|
944,697 | $66,742,843 | |
| 6 | PTGX |
Protagonist Therapeutics, Inc
|
281,832 | $34,546,966 |
All Filings in TVTX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $106,536,020 | 1,875,304 | Shares | Defined | 2026-07-29 | |
| 2026-03-31 | $53,432,424 | 1,798,466 | Shares | Defined | 2026-04-28 | |
| 2025-12-31 | $65,783,214 | 1,721,623 | Shares | Defined | 2026-02-05 | |
| 2025-09-30 | $38,232,065 | 1,599,668 | Shares | Defined | 2025-10-28 | |
| No filing history on record for this holder in this stock. | ||||||